{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T22:07:11Z","timestamp":1764540431521,"version":"3.37.3"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1176326","GNT1147569"],"award-info":[{"award-number":["GNT1176326","GNT1147569"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000923","name":"Australian Research Council","doi-asserted-by":"crossref","award":["DP190102789"],"award-info":[{"award-number":["DP190102789"]}],"id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Brain"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Synaptic degeneration is a precursor of synaptic and neuronal loss in neurodegenerative diseases such as Alzheimer\u2019s disease (AD) and frontotemporal dementia with tau pathology (FTD-tau), a group of primary tauopathies. A critical role in this degenerative process is assumed by enzymes such as the kinase Fyn and its counterpart, the phosphatase striatal-enriched tyrosine phosphatase 61 (STEP<jats:sub>61<\/jats:sub>). Whereas the role of Fyn has been widely explored, less is known about STEP<jats:sub>61<\/jats:sub> that localises to the postsynaptic density (PSD) of glutamatergic neurons. In dementias, synaptic loss is associated with an increased burden of pathological aggregates. Tau pathology is a hallmark of both AD (together with amyloid-\u03b2 deposition) and FTD-tau. Here, we examined STEP<jats:sub>61<\/jats:sub> and its activity in human and animal brain tissue and observed a correlation between STEP<jats:sub>61<\/jats:sub> and disease progression. In early-stage human AD, an initial increase in the level and activity of STEP<jats:sub>61<\/jats:sub> was observed, which decreased with the loss of the synaptic marker PSD-95; in FTD-tau, there was a reduction in STEP<jats:sub>61<\/jats:sub> and PSD-95 which correlated with clinical diagnosis. In APP23 mice with an amyloid-\u03b2 pathology, the level and activity of STEP<jats:sub>61<\/jats:sub> were increased in the synaptic fraction compared to wild-type littermates. Similarly, in the K3 mouse model of FTD-tau, which we assessed at two ages compared to wild-type, expression and activity of STEP<jats:sub>61<\/jats:sub> were increased with ageing. Together, these findings suggest that STEP contributes differently to the pathogenic process in AD and FTD-tau, and that its activation may be an early response to a degenerative process.<\/jats:p>","DOI":"10.1186\/s13041-023-00994-3","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T15:06:29Z","timestamp":1673622389000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Tyrosine phosphatase STEP61 in human dementia and in animal models with amyloid and tau pathology"],"prefix":"10.1186","volume":"16","author":[{"given":"Deonne","family":"Taylor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Kneynsberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marloes","family":"van Roijen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8501-7896","authenticated-orcid":false,"given":"J\u00fcrgen","family":"G\u00f6tz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,13]]},"reference":[{"key":"994_CR1","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1093\/jnen\/nlaa100","volume":"79","author":"SL Forrest","year":"2020","unstructured":"Forrest SL, et al. A practical approach to differentiate the frontotemporal tauopathy subtypes. J Neuropathol Exp Neurol. 2020;79:1122\u20136.","journal-title":"J Neuropathol Exp Neurol"},{"key":"994_CR2","doi-asserted-by":"publisher","first-page":"19014","DOI":"10.1073\/pnas.1013543107","volume":"107","author":"Y Zhang","year":"2010","unstructured":"Zhang Y, et al. Genetic reduction of striatal-enriched tyrosine phosphatase (STEP) reverses cognitive and cellular deficits in an Alzheimer\u2019s disease mouse model. Proc Natl Acad Sci U S A. 2010;107:19014\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"994_CR3","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0197-4580(95)00021-6","volume":"16","author":"H Braak","year":"1995","unstructured":"Braak H, Braak E. Staging of Alzheimer\u2019s disease-related neurofibrillary changes. Neurobiol Aging. 1995;16:271\u20138; discussion 278-284.","journal-title":"Neurobiol Aging"},{"key":"994_CR4","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41583-018-0054-8","volume":"19","author":"J G\u00f6tz","year":"2018","unstructured":"G\u00f6tz J, Bodea LG, Goedert M. Rodent models for Alzheimer disease. Nat Rev Neurosci. 2018;19:583\u201398.","journal-title":"Nat Rev Neurosci"},{"key":"994_CR5","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1074\/jbc.M008085200","volume":"276","author":"T Nakazawa","year":"2001","unstructured":"Nakazawa T, et al. Characterization of Fyn-mediated tyrosine phosphorylation sites on GluR epsilon 2 (NR2B) subunit of the N-methyl-D-aspartate receptor. J Biol Chem. 2001;276:693\u20139.","journal-title":"J Biol Chem"},{"key":"994_CR6","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13041-015-0148-4","volume":"8","author":"S-S Jang","year":"2015","unstructured":"Jang S-S, et al. Regulation of STEP61 and tyrosine-phosphorylation of NMDA and AMPA receptors during homeostatic synaptic plasticity. Mol Brain. 2015;8:55.","journal-title":"Mol Brain"},{"key":"994_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1001923","volume":"12","author":"J Xu","year":"2014","unstructured":"Xu J, et al. Inhibitor of the tyrosine phosphatase step reverses cognitive deficits in a mouse model of Alzheimer\u2019s disease. PLoS Biol. 2014;12: e1001923.","journal-title":"PLoS Biol"},{"key":"994_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.680118","volume":"9","author":"YAR Mahaman","year":"2021","unstructured":"Mahaman YAR, Huang F, Embaye KS, Wang X, Zhu F. The implication of STEP in synaptic plasticity and cognitive impairments in Alzheimer\u2019s disease and other neurological disorders. Front Cell Dev Biol. 2021;9:680118.","journal-title":"Front Cell Dev Biol"},{"key":"994_CR9","doi-asserted-by":"publisher","first-page":"5948","DOI":"10.1523\/JNEUROSCI.0157-10.2010","volume":"30","author":"P Kurup","year":"2010","unstructured":"Kurup P, et al. A\u03b2-mediated NMDA receptor endocytosis in Alzheimer\u2019s disease involves ubiquitination of the tyrosine phosphatase STEP61. J Neurosci. 2010;30:5948\u201357.","journal-title":"J Neurosci"},{"key":"994_CR10","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.15252\/embj.201797724","volume":"36","author":"C Li","year":"2017","unstructured":"Li C, G\u00f6tz J. Somatodendritic accumulation of Tau in Alzheimer\u2019s disease is promoted by Fyn-mediated local protein translation. EMBO J. 2017;36:3120\u201338.","journal-title":"EMBO J"},{"key":"994_CR11","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.neurobiolaging.2004.06.010","volume":"26","author":"S Boncristiano","year":"2005","unstructured":"Boncristiano S, et al. Neocortical synaptic bouton number is maintained despite robust amyloid deposition in APP23 transgenic mice. Neurobiol Aging. 2005;26:607\u201313.","journal-title":"Neurobiol Aging"},{"key":"994_CR12","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1093\/jnen\/nlz141","volume":"79","author":"JL Robinson","year":"2019","unstructured":"Robinson JL, et al. Primary tau pathology, not copathology, correlates with clinical symptoms in PSP and CBD. J Neuropathol Exp Neurol. 2019;79:296\u2013304.","journal-title":"J Neuropathol Exp Neurol"},{"key":"994_CR13","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2018101174","volume":"38","author":"HT Evans","year":"2019","unstructured":"Evans HT, Benetatos J, van Roijen M, Bodea L-G, G\u00f6tz J. Decreased synthesis of ribosomal proteins in tauopathy revealed by non-canonical amino acid labelling. EMBO J. 2019;38: e101174.","journal-title":"EMBO J"},{"key":"994_CR14","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.7150\/thno.34388","volume":"9","author":"R Pandit","year":"2019","unstructured":"Pandit R, Leinenga G, G\u00f6tz J. Repeated ultrasound treatment improves motor function and clears neuronal tau by autophagy. Theranostics. 2019;9:3754\u201367.","journal-title":"Theranostics"}],"container-title":["Molecular Brain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13041-023-00994-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13041-023-00994-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13041-023-00994-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T15:24:45Z","timestamp":1673623485000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularbrain.biomedcentral.com\/articles\/10.1186\/s13041-023-00994-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,13]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["994"],"URL":"https:\/\/doi.org\/10.1186\/s13041-023-00994-3","relation":{},"ISSN":["1756-6606"],"issn-type":[{"type":"electronic","value":"1756-6606"}],"subject":[],"published":{"date-parts":[[2023,1,13]]},"assertion":[{"value":"28 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal experimentation: All experiments were approved by and carried out in accordance with the guidelines of the Animal Ethics Committee of the University of Queensland (QBI\/554\/17\/NHMRC). Human brain tissue was received from the Sydney Brain Bank which is supported by Neuroscience Research Australia, the University of New South Wales and the National Health and Medical Research Council of Australia.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there is no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}